Updated on
Summary The results of the study were due to be presented later on Thursday at a conference in Prague.
A mid-stage trial of a new treatment from Novartis helped alleviate the symptoms for people suffering from plaque psoriasis, the Swiss firm said on Thursday.Approximately 2 percent of people suffer from plaque psoriasis, which can affect the hands, feet and nails and causes itching, scaling and pain, Novartis said.AIN457 was nearly three times more effective than a placebo at reducing moderate-to-severe plaque psoriasis on the hands and/or feet when given every week during the first month of treatment, it said.
